Loading stock data…
ZBH
$82.90+0.47 (+0.57%)
Market ClosedLast close May 1
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zimmer Biomet Holdings, Inc. in the Healthcare sector is trading at $82.90. The stock is currently near its 52-week low of $79.83, remaining 12.2% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why ZBH maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$82.90
Potential Downside
26.4%
Whystock Fair Value$61.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Hold
Mean target$98.52+18.8%
Range$83.00 – $130.00
Fundamentals
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.21
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Strong income play. Yield provides a meaningful total return floor.
103.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.49%
Volume
Today's trading volume
2.39M
Recent News
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
A Look At Zimmer Biomet (ZBH) Valuation After CFO Exit And Solid Quarterly Results
Earnings strength meets leadership uncertainty Zimmer Biomet Holdings (ZBH) delivered first quarter 2026 results that combined higher sales, firmer profitability and updated guidance with a sudden chief financial officer change that has become a key focus for investors. Sales for the quarter were US$2,086.7 million compared with US$1,909.1 million a year earlier, while net income was US$238.1 million versus US$182 million. Basic and diluted earnings per share from continuing operations were...
Stryker's Fundamentals 'Solidly Intact' Despite Cyber Disruption, RBC Says
Stryker's (SYK) fundamentals remain solidly intact despite a recent cybersecurity disruption that co
Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says
Zimmer Biomet's (ZBH) sales force productivity improvements, stable end markets and continued focus
Teva Pharmaceutical (TEVA): David Einhorn Likes This Pharma Stock
We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks 2nd on this list. Institutional sentiment towards Teva Pharmaceutical Industries Limited (NYSE:TEVA) has shifted significantly following Q4 2025 earnings, which many funds used as a signal to accumulate shares. The firm reported an Adjusted EPS […]